25 XP   0   0   10

Corvus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Corvus Pharmaceuticals Inc together

PenkeI guess you are interested in Corvus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Corvus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Corvus Pharmaceuticals Inc

I send you an email if I find something interesting about Corvus Pharmaceuticals Inc.

Quick analysis of Corvus Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Corvus Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.79
Expected worth in 1 year
$0.43
How sure are you?
21.6%

+ What do you gain per year?

Total Gains per Share
$-0.36
Return On Investment
-26.1%

For what price can you sell your share?

Current Price per Share
$1.36
Expected price per share
$1.05 - $1.65
How sure are you?
50%

1. Valuation of Corvus Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$1.36

Intrinsic Value Per Share

$-1.61 - $-1.68

Total Value Per Share

$-0.82 - $-0.89

2. Growth of Corvus Pharmaceuticals Inc (5 min.)




Is Corvus Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$38.6m$72.7m-$27.3m-60.4%

How much money is Corvus Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$6.9m-$12m$5m72.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Corvus Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#511 / 1019

Most Revenue
#981 / 1019

Most Profit
#479 / 1019

Most Efficient
#311 / 1019

What can you expect buying and holding a share of Corvus Pharmaceuticals Inc? (5 min.)

Welcome investor! Corvus Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Corvus Pharmaceuticals Inc.

What can you expect buying and holding a share of Corvus Pharmaceuticals Inc?

First you should know what it really means to hold a share of Corvus Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Corvus Pharmaceuticals Inc is $1.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Corvus Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Corvus Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.79. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Corvus Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-10.0%-0.14-10.1%-0.19-14.2%-0.16-12.1%-0.23-17.2%
Usd Book Value Change Per Share-0.11-8.4%-0.09-6.5%-0.21-15.4%-0.07-5.4%0.021.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.11-8.4%-0.09-6.5%-0.21-15.4%-0.07-5.4%0.021.6%
Usd Price Per Share1.76-1.61-1.07-2.62-5.56-
Price to Earnings Ratio-3.24--2.99--1.54--2.93--5.67-
Price-to-Total Gains Ratio-15.40-36.74--5.86-4.23--50.86-
Price to Book Ratio2.23-1.76-0.72-1.87-2.69-
Price-to-Total Gains Ratio-15.40-36.74--5.86-4.23--50.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.36
Number of shares735
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.07
Usd Total Gains Per Share-0.09-0.07
Gains per Quarter (735 shares)-65.31-53.70
Gains per Year (735 shares)-261.26-214.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-261-2710-215-225
20-523-5320-430-440
30-784-7930-644-655
40-1045-10540-859-870
50-1306-13150-1074-1085
60-1568-15760-1289-1300
70-1829-18370-1504-1515
80-2090-20980-1718-1730
90-2351-23590-1933-1945
100-2613-26200-2148-2160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.027.02.021.6%8.027.02.021.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.027.02.021.6%8.027.02.021.6%

Fundamentals of Corvus Pharmaceuticals Inc

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Fundamental data was last updated by Penke on 2024-04-11 05:10:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Corvus Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Corvus Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM--210.4%+210.4%
YOY--279.3%+279.3%
5Y--436.8%+436.8%
10Y--599.3%+599.3%
1.1.2. Return on Assets

Shows how efficient Corvus Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • -14.6% Return on Assets means that Corvus Pharmaceuticals Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Corvus Pharmaceuticals Inc:

  • The MRQ is -14.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.6%TTM-13.1%-1.5%
TTM-13.1%YOY-15.0%+1.9%
TTM-13.1%5Y-10.9%-2.2%
5Y-10.9%10Y-13.9%+3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.6%-13.6%-1.0%
TTM-13.1%-12.9%-0.2%
YOY-15.0%-11.9%-3.1%
5Y-10.9%-14.2%+3.3%
10Y-13.9%-16.2%+2.3%
1.1.3. Return on Equity

Shows how efficient Corvus Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • -17.2% Return on Equity means Corvus Pharmaceuticals Inc generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Corvus Pharmaceuticals Inc:

  • The MRQ is -17.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -15.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.2%TTM-15.5%-1.7%
TTM-15.5%YOY-18.0%+2.5%
TTM-15.5%5Y-13.0%-2.4%
5Y-13.0%10Y-16.4%+3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.2%-17.0%-0.2%
TTM-15.5%-16.1%+0.6%
YOY-18.0%-15.4%-2.6%
5Y-13.0%-20.0%+7.0%
10Y-16.4%-21.1%+4.7%

1.2. Operating Efficiency of Corvus Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Corvus Pharmaceuticals Inc is operating .

  • Measures how much profit Corvus Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY--288.4%+288.4%
5Y--475.2%+475.2%
10Y--624.7%+624.7%
1.2.2. Operating Ratio

Measures how efficient Corvus Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM-3.247-3.247
YOY-3.766-3.766
5Y-5.675-5.675
10Y-7.857-7.857

1.3. Liquidity of Corvus Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Corvus Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.07 means the company has $4.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 4.070. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.583. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.070TTM4.583-0.513
TTM4.583YOY4.976-0.392
TTM4.5835Y5.901-1.318
5Y5.90110Y13.585-7.683
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0703.930+0.140
TTM4.5834.251+0.332
YOY4.9765.436-0.460
5Y5.9016.045-0.144
10Y13.5856.363+7.222
1.3.2. Quick Ratio

Measures if Corvus Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.08 means the company can pay off $6.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 6.077. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.274. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.077TTM7.274-1.198
TTM7.274YOY7.493-0.219
TTM7.2745Y9.075-1.801
5Y9.07510Y22.690-13.615
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0773.629+2.448
TTM7.2744.065+3.209
YOY7.4935.397+2.096
5Y9.0755.993+3.082
10Y22.6906.277+16.413

1.4. Solvency of Corvus Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Corvus Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Corvus Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Corvus Pharmaceuticals Inc assets are financed with 15.1% credit (debt) and the remaining percentage (100% - 15.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 0.151. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.151. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.151TTM0.151-0.001
TTM0.151YOY0.155-0.003
TTM0.1515Y0.151+0.001
5Y0.15110Y0.190-0.039
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1510.332-0.181
TTM0.1510.334-0.183
YOY0.1550.268-0.113
5Y0.1510.366-0.215
10Y0.1900.390-0.200
1.4.2. Debt to Equity Ratio

Measures if Corvus Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.8% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Corvus Pharmaceuticals Inc:

  • The MRQ is 0.178. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.179. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.178TTM0.179-0.001
TTM0.179YOY0.185-0.006
TTM0.1795Y0.180-0.001
5Y0.18010Y0.143+0.037
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1780.381-0.203
TTM0.1790.390-0.211
YOY0.1850.334-0.149
5Y0.1800.434-0.254
10Y0.1430.466-0.323

2. Market Valuation of Corvus Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Corvus Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Corvus Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -3.24 means the investor is paying $-3.24 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Corvus Pharmaceuticals Inc:

  • The EOD is -2.506. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.243. Based on the earnings, the company is expensive. -2
  • The TTM is -2.990. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.506MRQ-3.243+0.737
MRQ-3.243TTM-2.990-0.253
TTM-2.990YOY-1.538-1.452
TTM-2.9905Y-2.932-0.058
5Y-2.93210Y-5.674+2.742
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.506-2.315-0.191
MRQ-3.243-2.560-0.683
TTM-2.990-2.664-0.326
YOY-1.538-4.122+2.584
5Y-2.932-6.258+3.326
10Y-5.674-6.108+0.434
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Corvus Pharmaceuticals Inc:

  • The EOD is -3.227. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.176. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.554. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.227MRQ-4.176+0.949
MRQ-4.176TTM-3.554-0.622
TTM-3.554YOY-1.971-1.582
TTM-3.5545Y-3.999+0.446
5Y-3.99910Y-7.639+3.640
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.227-3.067-0.160
MRQ-4.176-3.251-0.925
TTM-3.554-3.545-0.009
YOY-1.971-5.595+3.624
5Y-3.999-8.315+4.316
10Y-7.639-8.708+1.069
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Corvus Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.23 means the investor is paying $2.23 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Corvus Pharmaceuticals Inc:

  • The EOD is 1.724. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.231. Based on the equity, the company is underpriced. +1
  • The TTM is 1.758. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.724MRQ2.231-0.507
MRQ2.231TTM1.758+0.474
TTM1.758YOY0.716+1.042
TTM1.7585Y1.866-0.109
5Y1.86610Y2.693-0.827
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7241.905-0.181
MRQ2.2312.111+0.120
TTM1.7582.095-0.337
YOY0.7162.836-2.120
5Y1.8663.443-1.577
10Y2.6933.794-1.101
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Corvus Pharmaceuticals Inc.

3.1. Institutions holding Corvus Pharmaceuticals Inc

Institutions are holding 39.968% of the shares of Corvus Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC14.15960.2441694365400
2023-12-31Adams Street Partners LLC6.67971.7762327561600
2023-12-31Samlyn Capital, LLC5.09040.08752496259904953.7616
2023-09-30Bvf Inc2.79560.054137094700
2023-12-31Vanguard Group Inc2.75420.0001135063337010.2748
2023-12-31Renaissance Technologies Corp1.19790.001658743216568939.2867
2023-12-31BlackRock Inc1.06150520551-700-0.1343
2023-12-31Towerview LLC0.89090.46964368739439527.5624
2023-12-31Geode Capital Management, LLC0.73490.000136038000
2023-12-31Morgan Stanley - Brokerage Accounts0.529502596556714934.8815
2023-12-31Two Sigma Advisers, LLC0.48040.001235600-13300-5.3435
2023-12-31Susquehanna International Group, LLP0.44920.00012202969232872.1493
2023-12-31Two Sigma Investments LLC0.36850.0007180704-92303-33.8098
2023-12-31Bridgeway Capital Management, LLC0.30450.005614930000
2023-12-31State Street Corporation0.2822013840300
2023-12-31Connor Clark & Lunn Inv Mgmt Ltd0.14520.0006712083250.4585
2023-12-31MYDA Advisors LLC0.14480.04187101121973.1927
2023-12-31Northern Trust Corp0.132606501700
2023-12-31JACKSON SQUARE CAPITAL, LLC0.130.03616377300
2023-12-31Hikari Power Ltd0.10190.00844995900
Total 38.43352.727518847271+409976+2.2%

3.2. Funds holding Corvus Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.03510.0001998008572726.088
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.87420.00094286764360.1018
2024-02-29Fidelity Extended Market Index0.38360.0011188113-911-0.4819
2023-12-31Bridgeway Ultra-Small Company Market0.29710.13814570000
2023-09-30BlackRock Extended Mkt Composite0.17360.00098513400
2024-03-31BlackRock Extended Equity Market K0.15150.000974299270.0364
2024-02-29Fidelity Total Market Index0.11850.00025812900
2024-03-28iShares Micro-Cap ETF0.11650.01115710600
2024-02-29Fidelity Series Total Market Index0.09730.00024771700
2024-02-29Fidelity Nasdaq Composite Index0.09680.00074746100
2023-12-31NT Ext Equity Mkt Idx Fd - L0.06460.0013165700
2023-12-31Northern Trust Extended Eq Market Idx0.06460.0013165700
2023-12-31SSgA U.S. Extended Market Index Class I0.060.00192940000
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.05940.000129109-824607-96.5903
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.05940.00022910900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05730.00082809900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0460.000822567420.1865
2024-02-29Spartan Total Market Index Pool E0.04290.00022105700
2024-02-29Vanguard Balanced Index Inv0.04270.00012093500
2024-03-29Avantis US Small Cap Equity ETF0.03720.00321824800
Total 4.87830.16342392181-767741-32.1%

3.3. Insider Transactions

Insiders are holding 3.887% of the shares of Corvus Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-05-15Linda GraisBUY100002.45

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Corvus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.114-0.089-22%-0.209+83%-0.073-36%0.021-636%
Book Value Per Share--0.7890.924-15%1.483-47%1.461-46%1.588-50%
Current Ratio--4.0704.583-11%4.976-18%5.901-31%13.585-70%
Debt To Asset Ratio--0.1510.1510%0.155-2%0.1510%0.190-21%
Debt To Equity Ratio--0.1780.179-1%0.185-4%0.180-1%0.143+24%
Dividend Per Share----0%-0%-0%-0%
Eps---0.136-0.138+2%-0.194+43%-0.164+21%-0.235+73%
Free Cash Flow Per Share---0.105-0.122+16%-0.139+32%-0.163+55%-0.161+53%
Free Cash Flow To Equity Per Share---0.105-0.082-22%-0.063-41%-0.075-29%0.061-273%
Gross Profit Margin--1.0041.001+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---1.680--------
Intrinsic Value_10Y_min---1.613--------
Intrinsic Value_1Y_max---0.537--------
Intrinsic Value_1Y_min---0.527--------
Intrinsic Value_3Y_max---1.332--------
Intrinsic Value_3Y_min---1.277--------
Intrinsic Value_5Y_max---1.788--------
Intrinsic Value_5Y_min---1.684--------
Market Cap66692496.000-29%86307936.00078706953.000+10%52699331.490+64%128306064.198-33%272719028.864-68%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.724-29%2.2311.758+27%0.716+212%1.866+20%2.693-17%
Pe Ratio-2.506+23%-3.243-2.990-8%-1.538-53%-2.932-10%-5.674+75%
Price Per Share1.360-29%1.7601.605+10%1.075+64%2.616-33%5.561-68%
Price To Free Cash Flow Ratio-3.227+23%-4.176-3.554-15%-1.971-53%-3.999-4%-7.639+83%
Price To Total Gains Ratio-11.899+23%-15.39836.741-142%-5.858-62%4.234-464%-50.862+230%
Quick Ratio--6.0777.274-16%7.493-19%9.075-33%22.690-73%
Return On Assets---0.146-0.131-10%-0.150+3%-0.109-25%-0.139-5%
Return On Equity---0.172-0.155-10%-0.180+5%-0.130-24%-0.164-5%
Total Gains Per Share---0.114-0.089-22%-0.209+83%-0.073-36%0.021-636%
Usd Book Value--38684000.00045330750.000-15%72726000.000-47%71628650.000-46%77873945.946-50%
Usd Book Value Change Per Share---0.114-0.089-22%-0.209+83%-0.073-36%0.021-636%
Usd Book Value Per Share--0.7890.924-15%1.483-47%1.461-46%1.588-50%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.136-0.138+2%-0.194+43%-0.164+21%-0.235+73%
Usd Free Cash Flow---5167000.000-5992250.000+16%-6824000.000+32%-8009250.000+55%-7918614.243+53%
Usd Free Cash Flow Per Share---0.105-0.122+16%-0.139+32%-0.163+55%-0.161+53%
Usd Free Cash Flow To Equity Per Share---0.105-0.082-22%-0.063-41%-0.075-29%0.061-273%
Usd Market Cap66692496.000-29%86307936.00078706953.000+10%52699331.490+64%128306064.198-33%272719028.864-68%
Usd Price Per Share1.360-29%1.7601.605+10%1.075+64%2.616-33%5.561-68%
Usd Profit---6653000.000-6988000.000+5%-12062500.000+81%-8605500.000+29%-9259395.568+39%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.114-0.089-22%-0.209+83%-0.073-36%0.021-636%
 EOD+3 -5MRQTTM+14 -16YOY+20 -105Y+12 -1810Y+11 -19

4.2. Fundamental Score

Let's check the fundamental score of Corvus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.506
Price to Book Ratio (EOD)Between0-11.724
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.077
Current Ratio (MRQ)Greater than14.070
Debt to Asset Ratio (MRQ)Less than10.151
Debt to Equity Ratio (MRQ)Less than10.178
Return on Equity (MRQ)Greater than0.15-0.172
Return on Assets (MRQ)Greater than0.05-0.146
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Corvus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.462
Ma 20Greater thanMa 501.686
Ma 50Greater thanMa 1001.971
Ma 100Greater thanMa 2001.904
OpenGreater thanClose1.500
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets45,553
Total Liabilities6,869
Total Stockholder Equity38,684
 As reported
Total Liabilities 6,869
Total Stockholder Equity+ 38,684
Total Assets = 45,553

Assets

Total Assets45,553
Total Current Assets27,956
Long-term Assets17,597
Total Current Assets
Cash And Cash Equivalents 12,620
Short-term Investments 14,529
Net Receivables 63
Other Current Assets 744
Total Current Assets  (as reported)27,956
Total Current Assets  (calculated)27,956
+/-0
Long-term Assets
Property Plant Equipment 1,385
Long Term Investments 16,123
Long-term Assets Other 89
Long-term Assets  (as reported)17,597
Long-term Assets  (calculated)17,597
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,869
Long-term Liabilities0
Total Stockholder Equity38,684
Total Current Liabilities
Short-term Debt 1,374
Accounts payable 1,525
Other Current Liabilities 3,970
Total Current Liabilities  (as reported)6,869
Total Current Liabilities  (calculated)6,869
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -334,717
Accumulated Other Comprehensive Income -967
Other Stockholders Equity 374,363
Total Stockholder Equity (as reported)38,684
Total Stockholder Equity (calculated)38,684
+/-0
Other
Capital Stock5
Cash and Short Term Investments 27,149
Common Stock Shares Outstanding 49,039
Liabilities and Stockholders Equity 45,553
Net Debt -11,246
Net Invested Capital 38,684
Net Working Capital 21,087
Property Plant and Equipment Gross 6,082
Short Long Term Debt Total 1,374



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
12,529
0
0
101,630
98,459
157,224
156,921
149,763
140,150
127,101
115,487
104,788
94,775
148,689
137,919
127,222
118,232
112,309
103,116
92,470
83,646
73,797
64,177
55,862
85,529
109,236
109,394
119,323
109,455
101,290
92,541
80,348
68,240
58,197
58,041
51,942
45,553
45,55351,94258,04158,19768,24080,34892,541101,290109,455119,323109,394109,23685,52955,86264,17773,79783,64692,470103,116112,309118,232127,222137,919148,68994,775104,788115,487127,101140,150149,763156,921157,22498,459101,6300012,529
   > Total Current Assets 
12,529
0
0
100,720
95,663
154,072
153,495
146,036
134,896
123,115
111,634
100,867
90,055
145,166
134,433
124,532
114,597
107,004
98,145
86,421
77,982
69,843
60,561
52,509
44,259
68,809
69,120
78,757
69,451
64,367
58,885
51,272
42,303
34,467
37,910
33,094
27,956
27,95633,09437,91034,46742,30351,27258,88564,36769,45178,75769,12068,80944,25952,50960,56169,84377,98286,42198,145107,004114,597124,532134,433145,16690,055100,867111,634123,115134,896146,036153,495154,07295,663100,7200012,529
       Cash And Cash Equivalents 
12,517
0
0
79,599
4,105
4,065
4,343
5,576
134,896
10,487
34,095
44,104
90,055
102,565
28,068
40,747
114,597
38,976
30,183
9,067
5,154
23,498
20,705
22,976
16,455
45,104
58,915
72,295
63,458
31,460
28,477
24,588
13,159
9,654
7,658
20,105
12,620
12,62020,1057,6589,65413,15924,58828,47731,46063,45872,29558,91545,10416,45522,97620,70523,4985,1549,06730,18338,976114,59740,74728,068102,56590,05544,10434,09510,487134,8965,5764,3434,0654,10579,5990012,517
       Short-term Investments 
90,281
0
0
20,345
90,281
148,235
147,809
139,547
129,846
111,577
76,231
55,596
44,949
41,368
105,157
81,892
75,401
66,831
66,657
77,354
72,828
45,209
38,553
28,385
27,804
22,865
7,545
4,034
5,993
31,484
28,246
25,029
29,144
24,813
29,359
12,063
14,529
14,52912,06329,35924,81329,14425,02928,24631,4845,9934,0347,54522,86527,80428,38538,55345,20972,82877,35466,65766,83175,40181,892105,15741,36844,94955,59676,231111,577129,846139,547147,809148,23590,28120,3450090,281
       Net Receivables 
0
0
0
0
347
415
619
328
365
53
121
126
132
152
294
347
337
399
253
299
329
174
128
139
86
126
46
323
539
445
429
534
633
467
34
50
63
6350344676335344294455393234612686139128174329299253399337347294152132126121533653286194153470000
       Inventory 
0
0
0
0
722
735
0
209
-1,137
170
212
362
-852
516
400
215
-602
465
550
-924
-815
450
762
561
-492
506
2,534
2,007
32
848
1,338
724
-735
-598
723
662
0
0662723-598-7357241,338848322,0072,534506-492561762450-815-924550465-602215400516-852362212170-1,13720907357220000
   > Long-term Assets 
0
0
0
910
2,796
3,152
3,426
3,727
5,254
3,986
3,853
3,921
4,720
3,523
3,486
2,690
3,635
5,305
4,971
6,049
5,664
3,954
3,616
3,353
41,270
40,427
40,274
40,566
40,004
36,923
33,656
29,076
25,937
23,730
20,131
18,848
17,597
17,59718,84820,13123,73025,93729,07633,65636,92340,00440,56640,27440,42741,2703,3533,6163,9545,6646,0494,9715,3053,6352,6903,4863,5234,7203,9213,8533,9865,2543,7273,4263,1522,796910000
       Property Plant Equipment 
1,845
0
0
910
1,845
2,552
2,807
2,858
3,248
3,117
2,984
2,863
2,672
2,459
2,293
2,226
2,180
4,791
4,458
2,483
2,327
3,441
3,115
2,873
1,648
2,224
1,911
3,959
3,190
3,316
3,239
2,914
2,217
1,953
1,985
1,687
1,385
1,3851,6871,9851,9532,2172,9143,2393,3163,1903,9591,9112,2241,6482,8733,1153,4412,3272,4834,4584,7912,1802,2262,2932,4592,6722,8632,9843,1173,2482,8582,8072,5521,845910001,845
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,225
37,125
38,047
36,328
34,266
33,371
30,181
25,914
21,877
20,234
18,017
17,072
16,123
16,12317,07218,01720,23421,87725,91430,18133,37134,26636,32838,04737,12537,225000000000000000000000000
       Long-term Assets Other 
0
0
0
0
951
600
619
869
2,006
869
869
1,058
2,048
1,064
1,193
464
1,455
514
513
3,566
3,337
513
501
480
2,397
1,078
316
279
2,548
236
236
248
1,843
1,543
129
89
89
89891291,5431,8432482362362,5482793161,0782,3974805015133,3373,5665135141,4554641,1931,0642,0481,0588698692,0068696196009510000
> Total Liabilities 
2,677
0
0
126,940
129,560
4,674
4,953
6,853
7,349
8,876
10,705
11,051
9,940
11,461
10,520
8,375
7,896
11,612
13,462
12,057
12,535
13,762
13,337
13,512
13,381
14,851
12,991
14,175
12,293
11,568
12,155
15,667
12,125
9,330
8,558
7,653
6,869
6,8697,6538,5589,33012,12515,66712,15511,56812,29314,17512,99114,85113,38113,51213,33713,76212,53512,05713,46211,6127,8968,37510,52011,4619,94011,05110,7058,8767,3496,8534,9534,674129,560126,940002,677
   > Total Current Liabilities 
2,674
0
0
907
3,070
3,383
3,607
5,596
7,349
7,579
9,518
9,974
9,940
10,604
9,779
7,748
7,896
8,635
10,702
8,670
12,535
11,712
11,553
12,001
13,381
13,916
12,360
11,305
12,293
9,265
10,156
13,978
12,125
7,027
7,858
7,299
6,869
6,8697,2997,8587,02712,12513,97810,1569,26512,29311,30512,36013,91613,38112,00111,55311,71212,5358,67010,7028,6357,8967,7489,77910,6049,9409,9749,5187,5797,3495,5963,6073,3833,070907002,674
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
792
820
849
3,188
927
976
1,026
2,310
1,115
1,153
1,015
3,647
1,090
1,135
1,181
2,601
1,263
1,299
1,336
1,374
1,3741,3361,2991,2632,6011,1811,1351,0903,6471,0151,1531,1152,3101,0269769273,18884982079200000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
792
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000079200000000000000000
       Accounts payable 
57
0
0
447
1,575
1,577
1,320
2,416
1,900
2,421
4,138
3,576
3,454
3,499
2,255
1,885
1,998
2,264
2,638
1,910
2,448
3,356
2,779
2,571
3,467
4,910
2,865
2,334
1,565
2,189
2,650
4,227
1,976
7,027
2,098
1,404
1,525
1,5251,4042,0987,0271,9764,2272,6502,1891,5652,3342,8654,9103,4672,5712,7793,3562,4481,9102,6382,2641,9981,8852,2553,4993,4543,5764,1382,4211,9002,4161,3201,5771,5754470057
       Other Current Liabilities 
2,617
0
0
460
1,495
1,806
2,287
3,180
5,449
5,158
5,380
6,398
6,486
7,105
7,524
5,863
5,898
792
7,244
6,760
6,899
7,429
7,798
8,404
7,604
614
283
130
121
5,986
6,371
8,570
7,548
-1,263
137
262
3,970
3,970262137-1,2637,5488,5706,3715,9861211302836147,6048,4047,7987,4296,8996,7607,2447925,8985,8637,5247,1056,4866,3985,3805,1585,4493,1802,2871,8061,495460002,617
   > Long-term Liabilities 
0
0
0
126,033
126,490
1,291
1,346
1,257
1,405
1,297
1,187
1,077
971
857
741
627
869
2,977
2,760
3,387
2,310
2,050
1,784
1,511
1,232
935
631
2,870
2,601
2,303
1,999
1,689
1,373
2,303
700
354
0
03547002,3031,3731,6891,9992,3032,6012,8706319351,2321,5111,7842,0502,3103,3872,7602,9778696277418579711,0771,1871,2971,4051,2571,3461,291126,490126,033000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,977
2,760
2,538
0
2,050
1,784
1,511
0
935
631
2,870
0
2,303
1,999
1,689
0
1,040
700
354
0
03547001,04001,6891,9992,30302,87063193501,5111,7842,05002,5382,7602,97700000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,977
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,97700000000000000000
       Deferred Long Term Liability 
0
0
0
0
951
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000009510000
> Total Stockholder Equity
9,852
0
0
-25,310
-31,101
152,550
151,968
142,910
132,801
118,225
104,782
93,737
84,835
137,228
127,399
118,847
110,336
100,697
89,654
80,413
71,111
60,035
50,840
42,350
72,148
94,385
96,403
105,148
97,162
89,722
80,386
64,681
56,115
48,867
49,483
44,289
38,684
38,68444,28949,48348,86756,11564,68180,38689,72297,162105,14896,40394,38572,14842,35050,84060,03571,11180,41389,654100,697110,336118,847127,399137,22884,83593,737104,782118,225132,801142,910151,968152,550-31,101-25,310009,852
   Common Stock
2
0
0
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
4
4
5
5
5
5
5
5
5
5
5
5
5555555555443333333333332222222220002
   Retained Earnings Total Equity00-322,064-315,56100000-257,145-246,472-234,720-223,140-250,487-240,691-230,100-217,145-206,098-195,094-182,1160-159,963-149,466-137,835-123,534-111,605-98,888-83,907-67,871-56,785-46,488-37,84300000
   Accumulated Other Comprehensive Income 
0
0
0
3
-45
29
78
41
-39
-62
-52
-14
-41
-39
-20
-35
-34
11
39
34
29
43
53
12
4
6
1,387
1,375
1,869
1,987
339
-1,193
-563
-434
-1,368
-1,443
-967
-967-1,443-1,368-434-563-1,1933391,9871,8691,3751,3876412534329343911-34-35-20-39-41-14-52-62-39417829-453000
   Capital Surplus 
0
0
0
0
0
190,362
198,376
199,652
200,709
202,192
203,720
205,354
208,408
275,099
276,882
278,842
280,840
282,799
284,706
286,474
288,224
290,069
291,475
292,822
295,281
329,095
341,484
360,913
0
0
0
0
0
364,857
372,910
0
0
00372,910364,85700000360,913341,484329,095295,281292,822291,475290,069288,224286,474284,706282,799280,840278,842276,882275,099208,408205,354203,720202,192200,709199,652198,376190,36200000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
-45
0
0
144
440
33,138
41,455
49,889
200,709
202,192
203,720
205,354
208,408
275,099
276,882
278,842
280,840
282,799
284,706
286,474
288,224
290,069
291,475
292,822
295,281
329,095
341,484
360,913
361,669
362,408
363,083
363,741
364,361
364,857
372,910
373,791
374,363
374,363373,791372,910364,857364,361363,741363,083362,408361,669360,913341,484329,095295,281292,822291,475290,069288,224286,474284,706282,799280,840278,842276,882275,099208,408205,354203,720202,192200,70949,88941,45533,13844014400-45



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-151
Gross Profit-151-151
 
Operating Income (+$)
Gross Profit-151
Operating Expense-23,256
Operating Income-23,407-23,407
 
Operating Expense (+$)
Research Development16,526
Selling General Administrative6,881
Selling And Marketing Expenses151
Operating Expense23,25623,558
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,584
Other Finance Cost-3,106
Net Interest Income1,522
 
Pretax Income (+$)
Operating Income-23,407
Net Interest Income1,522
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-27,029-19,785
EBIT - interestExpense = -24,991
-27,029
-25,445
Interest Expense1,584
Earnings Before Interest and Taxes (EBIT)-23,407-25,445
Earnings Before Interest and Taxes (EBITDA)-23,256
 
After tax Income (+$)
Income Before Tax-27,029
Tax Provision-0
Net Income From Continuing Ops-30,192-27,029
Net Income-27,029
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses23,407
Total Other Income/Expenses Net-3,622-1,522
 

Technical Analysis of Corvus Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Corvus Pharmaceuticals Inc. The general trend of Corvus Pharmaceuticals Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Corvus Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Corvus Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 1.42 < 1.42 < 1.65.

The bearish price targets are: 1.33 > 1.23 > 1.05.

Tweet this
Corvus Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Corvus Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Corvus Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Corvus Pharmaceuticals Inc. The current macd is -0.14653811.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Corvus Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Corvus Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Corvus Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Corvus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCorvus Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Corvus Pharmaceuticals Inc. The current adx is 40.84.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Corvus Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Corvus Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Corvus Pharmaceuticals Inc. The current sar is 1.70907882.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Corvus Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Corvus Pharmaceuticals Inc. The current rsi is 24.46. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Corvus Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCorvus Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Corvus Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Corvus Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Corvus Pharmaceuticals Inc Daily Stochastic Oscillator ChartCorvus Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Corvus Pharmaceuticals Inc. The current cci is -155.48828008.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Corvus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCorvus Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Corvus Pharmaceuticals Inc. The current cmo is -61.4153802.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Corvus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCorvus Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Corvus Pharmaceuticals Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Corvus Pharmaceuticals Inc Daily Williams %R ChartCorvus Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Corvus Pharmaceuticals Inc. The current atr is 0.14454872.

Corvus Pharmaceuticals Inc Daily Average True Range (ATR) ChartCorvus Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Corvus Pharmaceuticals Inc. The current obv is 8,639,745.

Corvus Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCorvus Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Corvus Pharmaceuticals Inc. The current mfi is 19.93.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Corvus Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCorvus Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Corvus Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Corvus Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Corvus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.462
Ma 20Greater thanMa 501.686
Ma 50Greater thanMa 1001.971
Ma 100Greater thanMa 2001.904
OpenGreater thanClose1.500
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Corvus Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Corvus Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Corvus Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Corvus Pharmaceuticals Inc

I send you an email if I find something interesting about Corvus Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Corvus Pharmaceuticals Inc.

Receive notifications about Corvus Pharmaceuticals Inc in your mailbox!